# High Tide Subsidiary NuLeaf Naturals Pursues Medicare CBD Pilot Program > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/medicare-cbd-insurance-coverage-pilot-program/ > **Published:** 2026-04-01T14:05:51-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:32:53-04:00 > **Clinical Summary:** Explore Medicare CBD insurance coverage developments as NuLeaf Naturals seeks participation in a new Medicare CBD pilot program. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic MedicareCbdInsurance CoverageRegulatory PolicyAccess Why This Matters Medicare coverage for CBD would represent the first federal insurance recognition of [cannabis as medicine](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/), potentially transforming access for millions of older adults who currently pay out-of-pocket for [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/). This development could establish clinical protocols and quality standards that have been largely absent in the consumer CBD market. Clinical Summary NuLeaf Naturals is seeking participation in a proposed Medicare pilot program for CBD coverage, though no such official pilot has been announced by CMS. Medicare currently excludes all cannabis-derived products from coverage due to federal scheduling restrictions. Any legitimate Medicare CBD pilot would require significant regulatory changes and would likely focus on specific medical conditions with established evidence, such as treatment-resistant epilepsy where CBD already has [FDA approval](https://cedclinic.com/medicare-cannabis-reimbursement-policy-fda-approval/) as Epidiolex. Dr. Caplan’s Take “I’m skeptical of these claims until I see official CMS documentation — Medicare doesn’t typically announce pilots through industry press releases. If real, this would be groundbreaking, but patients shouldn’t adjust their treatment plans based on speculative insurance coverage.” Clinical Perspective 🧠 Clinicians should continue current evidence-based CBD recommendations regardless of insurance speculation. For patients interested in CBD, focus remains on discussing specific medical goals, potential drug interactions, and quality sourcing from reputable manufacturers with third-party testing. Any actual Medicare coverage would likely be limited to FDA-approved formulations initially. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20High%20Tide%20Subsidiary%20NuLeaf%20Naturals%20Pursues%20Participation%20in%20US%20Medicare%20CBD%20Pi...%20%40drcaplan&url=https%3A//www.cannabisbusinesstimes.com/business-issues-benchmarks/cbd-industry/news/15821093/high-tide-subsidiary-nuleaf-naturals-pursues-participation-in-us-medicare-cbd-pilot-program)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.cannabisbusinesstimes.com/business-issues-benchmarks/cbd-industry/news/15821093/high-tide-subsidiary-nuleaf-naturals-pursues-participation-in-us-medicare-cbd-pilot-program)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20High%20Tide%20Subsidiary%20NuLeaf%20Naturals%20Pursues%20Participation%20in%20US%20Medicare%20CBD%20Pi...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.cannabisbusinesstimes.com/business-issues-benchmarks/cbd-industry/news/15821093/high-tide-subsidiary-nuleaf-naturals-pursues-participation-in-us-medicare-cbd-pilot-program)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.cannabisbusinesstimes.com/business-issues-benchmarks/cbd-industry/news/15821093/high-tide-subsidiary-nuleaf-naturals-pursues-participation-in-us-medicare-cbd-pilot-program](https://www.cannabisbusinesstimes.com/business-issues-benchmarks/cbd-industry/news/15821093/high-tide-subsidiary-nuleaf-naturals-pursues-participation-in-us-medicare-cbd-pilot-program) Table of Contents - [FAQ](#FAQ)[Does Medicare currently cover CBD treatments?](#Does_Medicare_currently_cover_CBD_treatments) - [What regulatory changes are being considered for CBD insurance coverage?](#What_regulatory_changes_are_being_considered_for_CBD_insurance_coverage) - [Why is this development considered clinically relevant?](#Why_is_this_development_considered_clinically_relevant) - [How might expanded CBD coverage affect patient care?](#How_might_expanded_CBD_coverage_affect_patient_care) - [What should healthcare providers know about this development?](#What_should_healthcare_providers_know_about_this_development) - [Related](#Related) ## FAQ #### Does Medicare currently cover CBD treatments? Currently, Medicare does not cover [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) as they are not FDA-approved prescription medications. This represents a significant coverage gap for patients who might benefit from CBD treatments. #### What regulatory changes are being considered for CBD insurance coverage? Regulatory policy developments are emerging that could potentially expand insurance coverage for CBD treatments. These policy changes are still in early stages and require close monitoring by healthcare providers. #### Why is this development considered clinically relevant? This issue has notable clinical interest because it affects [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) to potentially beneficial treatments. The intersection of regulatory policy and insurance coverage directly impacts treatment options for patients seeking CBD therapies. #### How might expanded CBD coverage affect patient care? Expanded insurance coverage could improve [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) to CBD treatments that are currently out-of-pocket expenses. This could particularly benefit patients with chronic conditions who might benefit from CBD but cannot afford current costs. #### What should healthcare providers know about this development? Healthcare providers should stay informed about evolving regulatory policies regarding CBD coverage. These emerging findings represent important developments that could affect future prescribing options and [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) strategies. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “High Tide Subsidiary NuLeaf Naturals Pursues Participation in US Medicare CBD Pilot Program”, “url”: “https://www.cannabisbusinesstimes.com/business-issues-benchmarks/cbd-industry/news/15821093/high-tide-subsidiary-nuleaf-naturals-pursues-participation-in-us-medicare-cbd-pilot-program”, “datePublished”: “2026-04-01T13:22:49Z”, “about”: “high tide subsidiary nuleaf naturals pursues”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [CMS unveils new Medicare pilot for hemp, CBD products – Fierce Healthcare](https://cedclinic.com/medicare-pilot-hemp-cbd-coverage-expands-access/) Learn about the CMS announcement of a new Medicare pilot program focusing on hemp and CBD products, highlighting regulatory and coverage implications. [Read More](https://cedclinic.com/medicare-pilot-hemp-cbd-coverage-expands-access/) [Feds Finalize New Rule Allowing Some Hemp Products As Medicare Advantage Benefits](https://cedclinic.com/medicare-hemp-coverage-rule-expands-benefits/) Explore the finalized federal rule that permits certain hemp products to be included as Medicare Advantage benefits, marking a significant policy shift. [Discover Details](https://cedclinic.com/medicare-hemp-coverage-rule-expands-benefits/) [CBD Enters US Healthcare Through Medicare Pilot, But Coverage Remains Limited](https://cedclinic.com/medicare-cbd-coverage-limitations-healthcare-pilot/) Understand the current landscape of CBD coverage in US healthcare via Medicare pilots, including limitations and future prospects. [Learn More](https://cedclinic.com/medicare-cbd-coverage-limitations-healthcare-pilot/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).